Relyea Zuckerberg Hanson LLC Lowers Stock Position in Johnson & Johnson $JNJ

Key Points

• Relyea Zuckerberg Hanson LLC reduced its stake in Johnson & Johnson by 13.2% to 28,245 shares during the second quarter, with holdings valued at approximately $4.3 million.
• Johnson & Johnson reported Q2 earnings of $2.77 per share, surpassing analysts' expectations, with revenues of $23.74 billion, a 5.8% increase year-over-year.
• The company recently paid a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 2.8%.

Relyea Zuckerberg Hanson LLC lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,245 shares of the company's stock after selling 4,311 shares during the period. Relyea Zuckerberg Hanson LLC's holdings in Johnson & Johnson were worth $4,314,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Global Strategic Investment Solutions LLC raised its holdings in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock valued at $294,000 after purchasing an additional 65 shares during the last quarter. JSF Financial LLC increased its holdings in Johnson & Johnson by 2.2% during the second quarter. JSF Financial LLC now owns 2,993 shares of the company's stock worth $457,000 after buying an additional 65 shares during the last quarter. Elios Financial Group Inc. increased its holdings in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC increased its holdings in Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares during the last quarter. Finally, MBA Advisors LLC increased its holdings in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after buying an additional 68 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $188.95 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $455.06 billion, a PE ratio of 20.21, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $189.92. The company has a 50-day moving average price of $177.04 and a two-hundred day moving average price of $163.18.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business earned $2.82 earnings per share. The company's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a report on Friday. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Bank of America raised their price objective on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a report on Monday. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $189.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.